Announcement on Outgoing of Chairman
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Outgoing of Chairman
Filed with SSE ·
6ix hasn’t read this filing yet.
Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Earlier from Jiangsu Kanion Pharmaceutical
- Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
- Announcement on Passive Increase in Shareholding Ratio of Controlling Shareholder Due to Repurchase and Cancellation of Restricted Stocks by the Company Touching an Integer Multiple of 1%
- Announcement on Implementing Repurchase and Cancellation of All Remaining Restricted Stocks under the 2022 Annual Restricted Stocks Incentive Plan
- Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
- Announcement on Main Operating Data for Q1 2025
Later from Jiangsu Kanion Pharmaceutical
- Announcement on the Receipt of the Clinical Trial Approval Notice for KYS2301 Gel
- Announcement on Obtaining Drug Registration Certificate for Shenpu Granules
- Announcement on the Receipt of the Clinical Trial Approval Notice for Jianpi Shugan Guben Granules
- Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased Indications
- 2025 Semi-annual Report
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical